Apply for funding

Lewy Body Dementia 2026 Programme (coming soon)

Applicants must be primarily affiliated to a charitable or academic institution in the UK or Ireland.

Letter of Intent deadline: November 2026

The Lewy Body Dementia programme provides catalyst funding to support high-risk, high-reward, translational research that accelerates the development of biomarkers, as well as treatments, for Dementia with Lewy Bodies and Parkinson’s Disease Dementia.

Project Details:

• Biomarkers must be under development for human disease diagnosis, prognosis, stratification to clinical trials, measuring disease progression, and/or to predict/measure response to therapy.
• Treatments must target the management of neuropsychiatric symptoms and are not limited to pharmacological approaches.

Funding available: up to £750,000 for later-stage validation or small scale-up studies.

Additional information about this programme including full details of application criteria, funding eligibility, scope and our intellectual property policy, will be provided shortly.

Characterisation of Novel Biomarkers for Neurodegenerative Diseases of Ageing 2026 Programme (closed)

Applicants must be primarily affiliated to an institution in the UK or Ireland.

Letter of Intent deadline: April 2, 2026, 5:00 PM GMT

One of our research funding programmes for 2026 focuses on the development of novel biomarkers that are intended to improve the treatment, and accelerate the development, of new therapeutics for neurodegenerative diseases of ageing (NDAs).

We define novel biomarkers as those that are not approved for clinical use and have been insufficiently studied. These biomarkers must have the potential to be used in the diagnosis of, prognosis of (including rate of progression), efficient conduct of clinical trials for, and/or determination of treatment response in these diseases.

Three projects were awarded through the Novel Biomarkers 2024 Programme. To learn more about these projects, click here.

Funding is available at two tiers: (1) up to £350,000 for proof-of-concept and early validation studies and (2) up to £750,000 for later-stage validation or small scale-up studies.

For more information about this programme including full details of application criteria, funding eligibility, diseases that fall within our remit and our intellectual property policy, see our programme guide below.

We welcome you to contact us with any program-related inquiries including questions about the eligibility or fit of your project. Please send your questions to Teenu Sanjeevan, Director, Neuroscience at contact@galenhilarywestonfoundation.org

Relevant documents:

• Programme Guide